HCW Biologics Inc.(HCWB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $6.7M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
HCWB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for HCW Biologics Inc. (HCWB), a Healthcare sector company. HCWB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $6.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), HCW Biologics Inc. reports quarterly revenue of $6.5M, net income of $3.5M, free cash flow of $-1.6M. Top institutional holders of HCWB by reported 13-F value include GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, Tower Research Capital (TRC), based on the most recent SEC filings. HCWB trades on the Nasdaq exchange and files with the SEC under CIK 1828673. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HCWB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HCW Biologics Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$6.5M
Net Income
Q1 2026
$3.5M
Free Cash Flow
Q1 2026
$-1.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-97.9% YoYNet Income
+73.5% YoYOperating Income
+55.3% YoYEPS (Diluted)
+65.7% YoYTotal Assets
-18.9% YoYTotal Debt
-50.3% YoYOp. Cash Flow
+5.9% YoY| Metric | FY 2025 | FY 2024 | FY 2021 | FY 2019 |
|---|---|---|---|---|
| Revenue | $54.2K -97.9% | $2.6M | $0.00 | — |
| Net Income | $-8.0M +73.5% | $-30.0M -133.4% | $-12.9M | — |
| Operating Income | $-13.2M +55.3% | $-29.5M -120.4% | $-13.4M | — |
| EPS (Diluted) | $-10.63 +65.7% | $-30.96 -4387.0% | $-0.69 | — |
| Total Assets | $24.5M -18.9% | $30.2M -43.5% | $53.5M | — |
| Total Debt | $6.8M -50.3% | $13.7M | $0.00 | — |
| Operating Cash Flow | $-13.4M +5.9% | $-14.2M -29.6% | $-11.0M | — |
Get alerted when HCWB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for HCW Biologics Inc. including:
Top Institutional Holders of HCWB
GEODE CAPITAL MANAGEMENT, LLC
$12.9K35,886 shCITADEL ADVISORS LLC
$9.4K26,083 shTower Research Capital LLC (TRC)
$5.3K14,839 shJANE STREET GROUP, LLC
$5.1K14,134 shVANGUARD CAPITAL MANAGEMENT LLC
$4.3K12,023 shCITIGROUP INC
$3.8K10,528 shGolden State Wealth Management, LLC
$3.6K10,000 shUBS Group AG
$3.3K9,221 shVANGUARD FIDUCIARY TRUST CO
$685.001,903 shWELLS FARGO & COMPANY/MN
$360.001,000 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $12.9K | 35,886 |
| CITADEL ADVISORS LLC | $9.4K | 26,083 |
| Tower Research Capital LLC (TRC) | $5.3K | 14,839 |
| JANE STREET GROUP, LLC | $5.1K | 14,134 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.3K | 12,023 |
| CITIGROUP INC | $3.8K | 10,528 |
| Golden State Wealth Management, LLC | $3.6K | 10,000 |
| UBS Group AG | $3.3K | 9,221 |
| VANGUARD FIDUCIARY TRUST CO | $685.00 | 1,903 |
| WELLS FARGO & COMPANY/MN | $360.00 | 1,000 |
More Healthcare Companies
View all Healthcare →Put HCWB on your watchlist
Track score changes the day HCW Biologics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is HCWB a good stock to buy?
13F Pro's AI-powered analysis of HCW Biologics Inc. (HCWB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HCWB are available on the HCWB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own HCWB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HCWB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HCW Biologics Inc.'s investment landscape.